Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Leukemia - 1 Jun 2015

Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N

Abstract excerpt

We investigated the influence of molecular status on disease characteristics and clinical outcome in young patients (⩽ 40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) or early/prefibrotic primary myelofibrosis (early-PMF). Overall, 217 patients with ET (number 197) and early-PMF (number 20) were included in the analysis. Median follow-up time was 10.2 years. The cumulative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Cytogenetic Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Neoplasm Staging

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Share to Survival Rate

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 25801912
DOI: 10.1038/leu.2015.87

Genes

CALR
EFS
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.PMID 25801912Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.Semantic proximity Read ↗

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.Semantic proximity Read ↗

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcomeSemantic proximity Read ↗

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.Semantic proximity Read ↗

[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].Semantic proximity Read ↗

One thousand patients with essential thrombocythemia: the Mayo Clinic experience.Semantic proximity Read ↗

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.Semantic proximity Read ↗

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.Semantic proximity Read ↗

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Semantic proximity Read ↗

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.Semantic proximity Read ↗

Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.